AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31226196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti‐reinforced dense polytetrafluoroethylene (d‐PTFE) membrane (Group A)
Number of subjects: 40
Study 31226196 — intervention group
Group type: COMPARATOR
Intervention: Ti‐mesh and a cross‐linked collagen membrane (Group B)
Number of subjects: 40
Study 28381478 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3 (genetic group) - FTO risk carriers (AA/AT)
Number of subjects: 683
Study 28381478 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3 (genetic group) - FTO nonrisk carriers (TT)
Number of subjects: 683
Study 28381478 — intervention group
Group type: COMPARATOR
Intervention: Level 0 (control group)
Number of subjects: 683
Study 28381478 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 (dietary group)
Number of subjects: 683
Study 28381478 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 (phenotype group)
Number of subjects: 683
Study 25881122 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in shared decision making and use of a decision aid
Number of subjects: 16
Study 25881122 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 23592248 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 120
Study 23592248 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 120
Study 23592248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Vitamin A Supplementation (VAS)
Number of subjects: 4345
Study 21853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Vitamin A Supplementation (VAS) in girls
Number of subjects: 4345
Study 21853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Vitamin A Supplementation (VAS) with FU-VAS in girls
Number of subjects: 4345
Study 21853099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4345
Study 19207759 — intervention group
Group type: COMPARATOR
Intervention: PVI
Number of subjects: 98
Study 19207759 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + CFAE
Number of subjects: 98
Study 19207759 — intervention group
Group type: EXPERIMENTAL
Intervention: CFAE ablation after PVI
Number of subjects: 98
Study 17156852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention utilized in the primary care trial (specific details not provided)
Number of subjects: 386
Study 17156852 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor medication adherence in the 30 days prior to the trial
Number of subjects: 386
Study 17156852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower self-efficacy to manage depression
Number of subjects: 386
Study 17156852 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores on the Child Trauma Questionnaire
Number of subjects: 386
Study 15114308 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic measurement of length
Number of subjects: 12
Study 15114308 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements by different endoscopists
Number of subjects: 12
Study 11207014 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at 40% of maximal static inspiratory pressure (Pimax) for 20 min a day, 5 days a week for 6 weeks.
Number of subjects: 16
Study 11207014 — intervention group
Group type: COMPARATOR
Intervention: Sham training at a load of 10% of Pimax for 20 min a day, 5 days a week for 6 weeks.
Number of subjects: 16
Study 9042987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 105
Study 9042987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg daily (for unhealed or symptomatic patients at week 4)
Number of subjects: 105
Study 9042987 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 105
Study 7940140 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 45
Study 7940140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tension glaucoma group (LTG)
Number of subjects: 45
Study 7940140 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects) at IOP increment of 5 mmHg
Number of subjects: 45
Study 7940140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tension glaucoma group (LTG) at IOP increment of 5 mmHg
Number of subjects: 45
Study 7940140 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects) at IOP increment of 10 mmHg
Number of subjects: 45
Study 7940140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tension glaucoma group (LTG) at IOP increment of 10 mmHg
Number of subjects: 45
Study 7940140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at IOP increments of 5 or 10 mmHg
Number of subjects: 45
Study 2853297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0
Study 2853297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31614418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose maize starch (HMS)
Number of subjects: 14
Study 31614418 — intervention group
Group type: COMPARATOR
Intervention: Native banana starch (NBS)
Number of subjects: 14
Study 31614418 — intervention group
Group type: COMPARATOR
Intervention: Digestible maize starch (DMS)
Number of subjects: 14
Study 28549870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography + quantitative transmission ultrasound
Number of subjects: 37
Study 28549870 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence scores from readers
Number of subjects: 37
Study 26089641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 8 mg
Number of subjects: 31
Study 26089641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 16 mg
Number of subjects: 31
Study 26089641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 32 mg
Number of subjects: 31
Study 26089641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 64 mg
Number of subjects: 31
Study 26089641 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 128 mg
Number of subjects: 31
Study 24238498 — intervention group
Group type: EXPERIMENTAL
Intervention: Changfu dialysis solution 6 L
Number of subjects: 4
Study 24238498 — intervention group
Group type: COMPARATOR
Intervention: Baxter dialysis solution 6 L
Number of subjects: 4
Study 24238498 — intervention group
Group type: EXPERIMENTAL
Intervention: Changfu dialysis solution 8 L
Number of subjects: 4
Study 24238498 — intervention group
Group type: COMPARATOR
Intervention: Baxter dialysis solution 8 L
Number of subjects: 4
Study 24238498 — intervention group
Group type: EXPERIMENTAL
Intervention: Changfu 6 L vs 8 L
Number of subjects: 4
Study 24238498 — intervention group
Group type: EXPERIMENTAL
Intervention: Changfu before technology optimization
Number of subjects: 4
Study 21664515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 20 mcg/drospirenone 3 mg 24/4
Number of subjects: 449
Study 21664515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 19933719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (low to moderate doses)
Number of subjects: 284
Study 17300962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg i.v.)
Number of subjects: 8
Study 17300962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 14732655 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate PDT
Number of subjects: 101
Study 14732655 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 101
Study 11570022 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder
Number of subjects: 1908
Study 11570022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail reminder
Number of subjects: 1908
Study 11570022 — intervention group
Group type: COMPARATOR
Intervention: Routine publicity
Number of subjects: 1908
Study 9782690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions for patients with hypertension
Number of subjects: 231
Study 9782690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions for patients with COPD
Number of subjects: 231
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE questionnaire
Number of subjects: 121
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of acetate
Number of subjects: 121
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean corpuscular volume (MCV)
Number of subjects: 121
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma glutamyl transferase (GGT)
Number of subjects: 121
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated haemoglobin (Hb A1c)
Number of subjects: 121
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CAGE questionnaire and other tests
Number of subjects: 121
Study 7945575 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective variables (MCV, acetate, GGT)
Number of subjects: 121
Study 3075425 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu340 IUD
Number of subjects: 431
Study 3075425 — intervention group
Group type: COMPARATOR
Intervention: MLCu375
Number of subjects: 431
Study 3075425 — intervention group
Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 431
Study 29728515 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET (I-PET)
Number of subjects: 465
Study 29728515 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-Treatment PET (EoT-PET)
Number of subjects: 465
Study 27519791 — intervention group
Group type: EXPERIMENTAL
Intervention: PNA clamping-assisted fluorescence melting curve analysis for EGFR mutations
Number of subjects: 194
Study 27519791 — intervention group
Group type: EXPERIMENTAL
Intervention: PNA clamping-assisted fluorescence melting curve analysis for KRAS mutations
Number of subjects: 194
Study 27519791 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma mutation status
Number of subjects: 194
Study 26715701 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion analgesia
Number of subjects: 75
Study 26715701 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular infusion analgesia
Number of subjects: 75
Study 23561916 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxants and celecoxib
Number of subjects: 150
Study 23561916 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxants alone
Number of subjects: 150
Study 23561916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 20628590 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi (Trandolapril 2 mg/day)
Number of subjects: 90
Study 20628590 — intervention group
Group type: COMPARATOR
Intervention: Non-ACEi therapy
Number of subjects: 90
Study 19041835 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone with standard treatment
Number of subjects: 0
Study 19041835 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study 16439590 — intervention group
Group type: EXPERIMENTAL
Intervention: HiPro formula (3.6 g/100 kcal)
Number of subjects: 18
Study 16439590 — intervention group
Group type: COMPARATOR
Intervention: RegPro formula (3.0 g/100 kcal)
Number of subjects: 18
Study 12910587 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow VF‐NCPAP
Number of subjects: 18
Study 12910587 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabella VF‐NCPAP
Number of subjects: 18
Study 12910587 — intervention group
Group type: COMPARATOR
Intervention: Both VF‐NCPAP devices
Number of subjects: 18
Study 10975587 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg daily
Number of subjects: 26
Study 10975587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10975587 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 26
Study 8885035 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week rehabilitation programme
Number of subjects: 14
Study 8885035 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 14
Study 1393157 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 38
Study 1393157 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy (exposure and response prevention)
Number of subjects: 38
Study 1393157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 1393157 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 38
Study 3900907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract administered at birth
Number of subjects: 32
Study 3900907 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 32
Study 30358737 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants with different metabolite clusters
Number of subjects: 183
Study 29100885 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (CO) at 100 to 200 parts per million for 2 hours daily, twice weekly, for 12 weeks
Number of subjects: 58
Study 29100885 — intervention group
Group type: COMPARATOR
Intervention: Inhaled 21% oxygen (placebo) for 2 hours daily, twice weekly, for 12 weeks
Number of subjects: 58
Study 29100885 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (CO)
Number of subjects: 58
Study 26471344 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP; 1.7 g kg(‐1) per day; n=31)
Number of subjects: 61
Study 26471344 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NP; 0.9 g kg(‐1) per day; n=30)
Number of subjects: 61
Study 24708516 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker exercise once a day for 6 weeks
Number of subjects: 19
Study 24708516 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker exercise three times a day for 6 weeks
Number of subjects: 19
Study 24708516 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 4 weeks post-exercise
Number of subjects: 19
Study 23234151 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Huatan Fang
Number of subjects: 60
Study 23234151 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E Recipe
Number of subjects: 60
Study 20492037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi programme (26 weeks)
Number of subjects: 139
Study 20492037 — intervention group
Group type: COMPARATOR
Intervention: Normal daily activities (Control group)
Number of subjects: 139
Study 18936502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led disease management intervention (12-month program with 1 face-to-face encounter and regular telephone follow-up)
Number of subjects: 0
Study 18936502 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 18936502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led disease management intervention (sensitivity analysis)
Number of subjects: 0
Study 15860509 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept/methotrexate combination
Number of subjects: 0
Study 15860509 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study 15860509 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 12824094 — intervention group
Group type: EXPERIMENTAL
Intervention: Theaflavin-enriched green tea extract (375 mg)
Number of subjects: 240
Study 12824094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 10638896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.2 mg/kg)
Number of subjects: 23
Study 10638896 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 23
Study 8797123 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographically defined vertebral deformity
Number of subjects: 15570
Study 8797123 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 15570
Study 8797123 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical variation
Number of subjects: 15570
Study 1536481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine plus placebo
Number of subjects: 39
Study 1536481 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine plus placebo
Number of subjects: 39
Study 1536481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine plus cimetidine
Number of subjects: 39
Study 6321689 — intervention group
Group type: EXPERIMENTAL
Intervention: FACP/weekly doxorubicin
Number of subjects: 100
Study 6321689 — intervention group
Group type: COMPARATOR
Intervention: FACP/standard doxorubicin
Number of subjects: 100
Study 31513144 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush Curaprox CS 5460 together with single‐tufted brush Curaprox CS 1006
Number of subjects: 30
Study 31513144 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush Curaprox CS 5460
Number of subjects: 30
Study 30099212 — intervention group
Group type: EXPERIMENTAL
Intervention: NLC with higher MAPL content
Number of subjects: 0
Study 30099212 — intervention group
Group type: EXPERIMENTAL
Intervention: NLC with lower MAPL content
Number of subjects: 0
Study 30099212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-sized emulsions with increased oil phase volume
Number of subjects: 0
Study 30099212 — intervention group
Group type: EXPERIMENTAL
Intervention: NLC-based formulations
Number of subjects: 0
Study 30099212 — intervention group
Group type: COMPARATOR
Intervention: Emulsion
Number of subjects: 0
Study 27042735 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal inactivated influenza vaccine without a lipid adjuvant
Number of subjects: 100
Study 27042735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24796768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g LT‐02
Number of subjects: 156
Study 24796768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g LT‐02
Number of subjects: 156
Study 24796768 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 g LT‐02
Number of subjects: 156
Study 24796768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 23051558 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination (T80/H25)
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation alone
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (separately or together with iron)
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined zinc and iron supplementation
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iron and zinc supplementation
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and iron supplementation (together or separately)
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate delivery of iron and zinc
Number of subjects: 0
Study 19904293 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate and combined administration of iron and zinc
Number of subjects: 0
Study 17678782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with 5 doses each side, total dosage 40 mL (300 mg) via parasternal intercostal injection
Number of subjects: 88
Study 17678782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 88
Study 17678782 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 88
Study 15765326 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg initial IV injection, then 3 mg every 5 minutes)
Number of subjects: 54
Study 15765326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg/kg initial IV injection, then 30 microg every 5 minutes)
Number of subjects: 54
Study 11510921 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin coated circuits combined with leukocyte filtration (group I)
Number of subjects: 52
Study 11510921 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 52
Study 9764623 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. hypotonic fluid
Number of subjects: 84
Study 9764623 — intervention group
Group type: EXPERIMENTAL
Intervention: oral water
Number of subjects: 84
Study 9764623 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. isotonic fluid
Number of subjects: 84
Study 9764623 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 84
Study 7844228 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous successful IVF trials (Group A)
Number of subjects: 257
Study 7844228 — intervention group
Group type: COMPARATOR
Intervention: New IVF patients (Group B)
Number of subjects: 257
Study 3802722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough test after pharmacological autonomic blockade (atropine)
Number of subjects: 8
Study 3802722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough test in diabetic patients with autonomic neuropathy
Number of subjects: 8
Study 3802722 — intervention group
Group type: COMPARATOR
Intervention: Cough test in healthy subjects
Number of subjects: 8
Study 3802722 — intervention group
Group type: COMPARATOR
Intervention: Intense contraction of arm muscles (handgrip)
Number of subjects: 8
Study 30015069 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention package including detection, treatment, and control of cardiovascular risk factors by nonphysician health workers, free dispensation of combination antihypertensive and cholesterol-lowering medications, and support from a treatment supporter.
Number of subjects: 1376
Study 30015069 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1376
Study 30015069 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention package.
Number of subjects: 1376
Study 27036491 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy
Number of subjects: 115
Study 27036491 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast therapy
Number of subjects: 115